biote Corp
NASDAQ:BTMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
biote Corp
Cost of Revenue
biote Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
b
|
biote Corp
NASDAQ:BTMD
|
Cost of Revenue
-$54.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cost of Revenue
-$30.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cost of Revenue
-$84.5m
|
CAGR 3-Years
80%
|
CAGR 5-Years
62%
|
CAGR 10-Years
32%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cost of Revenue
-$15.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cost of Revenue
-$14.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cost of Revenue
-$12.4B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-9%
|
|
biote Corp
Glance View
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas. The company went IPO on 2021-03-02. The firm provides components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. Its Biote Method is a comprehensive, end-to-end practice-building platform that provides Biote-certified practitioners with components specifically developed for practitioners in the hormone optimization space, such as Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The firm trains practitioners how to identify and treat early indicators of hormone-related aging conditions. The company also sells a complementary Biote-branded line of dietary supplements.
See Also
What is biote Corp's Cost of Revenue?
Cost of Revenue
-54.9m
USD
Based on the financial report for Dec 31, 2025, biote Corp's Cost of Revenue amounts to -54.9m USD.
What is biote Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-4%
Over the last year, the Cost of Revenue growth was 6%.
